01913nas a2200325   4500000000100000008004100001260002300042653001500065653002700080653001200107653000800119653001600127653001600143653001700159653002400176100000900200700000900209700000900218700001000227700000900237700000900246700001000255700001200265245007000277856011200347300000900459490000700468520109800475022001401573       2024                            d  bFrontiers Media SA10aImmunology10aImmunology and Allergy10aleprosy10aMDT10aProphylaxis10aRifapentine10aImmune cells10aSusceptibility gene1 aLi X1 aMa Y1 aLi G1 aJin G1 aXu L1 aLi Y1 aWei P1 aZhang L00aLeprosy: treatment, prevention, immune response and gene function  uhttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1298749/pdf?isPublishedV2=false  a1-180 v153 a<p>Since the leprosy cases have fallen dramatically, the incidence of leprosy has remained stable over the past years, indicating that multidrug therapy seems unable to eradicate leprosy. More seriously, the emergence of rifampicin-resistant strains also affects the effectiveness of treatment. Immunoprophylaxis was mainly carried out through vaccination with the BCG but also included vaccines such as LepVax and MiP. Meanwhile, it is well known that the infection and pathogenesis largely depend on the host’s genetic background and immunity, with the onset of the disease being genetically regulated. The immune process heavily influences the clinical course of the disease. However, the impact of immune processes and genetic regulation of leprosy on pathogenesis and immunological levels is largely unknown. Therefore, we summarize the latest research progress in leprosy treatment, prevention, immunity and gene function. The comprehensive research in these areas will help elucidate the pathogenesis of leprosy and provide a basis for developing leprosy elimination strategies.</p>
  a1664-3224